Buprenorphine (DB00921): A Comprehensive Pharmacological and Clinical Review

Introduction and Drug Identity

Overview of Buprenorphine's Role in Modern Therapeutics

Buprenorphine is a semi-synthetic opioid medication derived from thebaine, an alkaloid of the opium poppy, Papaver somniferum.[1] It occupies a unique and critical position in modern medicine, serving dual roles as a potent analgesic and as a cornerstone therapy for Opioid Use Disorder (OUD).[2] First patented in 1965 and approved for medical use in the United States in 1981, its global importance is underscored by its inclusion on the World Health Organization's List of Essential Medicines.[2]

The therapeutic utility of buprenorphine is rooted in its distinctive pharmacological profile. It functions as a partial agonist at the mu-opioid (μ) receptor and an antagonist at the kappa-opioid (κ) receptor.[4] This mixed agonist-antagonist activity fundamentally distinguishes it from full opioid agonists such as methadone and heroin, conferring a balance of efficacy and a more favorable safety profile.[5] This profile allows it to alleviate withdrawal symptoms and cravings in individuals with OUD while presenting a lower risk of euphoria and respiratory depression.[5] Consequently, buprenorphine has become a first-line agent in Medication-Assisted Treatment (MAT), also referred to as Medications for Opioid Use Disorder (MOUD), significantly expanding access to care beyond the confines of traditional opioid treatment programs.[5]

The complex interplay between buprenorphine's chemical structure and its receptor interactions dictates its clinical effects, from its therapeutic benefits to its specific risks, such as the potential for precipitating withdrawal. A thorough understanding of its properties is therefore essential for its safe and effective clinical application. The structural complexity of buprenorphine is a direct predictor of its unique pharmacological actions. The molecule's highly modified morphinane scaffold, which includes an etheno bridge, a large N-cyclopropylmethyl group, and a bulky tertiary alcohol side chain, is fundamentally responsible for its behavior at the receptor level.[9] These structural features create strong binding forces (high affinity), prevent the receptor from achieving full activation (partial agonism), and cause the molecule to remain bound for an extended period (slow dissociation). Thus, the chemical architecture of buprenorphine is the origin of its entire clinical profile.

Chemical and Physical Properties

Buprenorphine is classified as a small molecule drug with the DrugBank accession number DB00921 [User Query]. Chemically, it is a morphinane alkaloid and a derivative of thebaine.[10] Its structure is defined as a 7,8-dihydromorphine 6-O-methyl ether featuring a methylene-methylene bridge between carbon positions 6 and 14, a cyclopropyl substitution on the nitrogen atom, and a 2-hydroxy-3,3-dimethylbutan-2-yl group at position 7.[9] In its pure form, buprenorphine is a white crystalline solid or powder.[9]

Its solubility characteristics are critical to its formulation and administration. It is very slightly soluble in water, freely soluble in acetone, soluble in methanol, and slightly soluble in cyclohexane.[9] Importantly, it dissolves in dilute acids, which facilitates its formulation as a hydrochloride salt for various pharmaceutical preparations.[9] There are some discrepancies in the literature regarding its precise physical constants. For example, its melting point has been reported as both approximately 217 °C in an FDA chemistry review and as 260-262 °C in a chemical supplier database.[9] Similarly, its pKa has been reported as 8.24 and, alternatively, as two values, 8.5 and 10.0.[9] These variations may be attributable to differences in the crystalline polymorph tested, the salt form (base versus hydrochloride), or the experimental methodologies employed. The data from regulatory filings, such as the FDA review, are generally considered to be the most rigorously verified.

Table 1: Chemical and Physical Identifiers of Buprenorphine

Identifier	Value	Source(s)
Drug Name	Buprenorphine	User Query
DrugBank ID	DB00921	User Query, 76
Type	Small Molecule	User Query
CAS Number	52485-79-7	User Query, 9
Molecular Formula	C29​H41​NO4​	9
Molecular Weight	467.65 g/mol	9
IUPAC Name	(5α,6β,14β,18R)−17−(cyclopropylmethyl)−18−−6−methoxy−18,19−dihydro−4,5−epoxy−6,14−ethenomorphinan−3−ol	10
Other Names	6,14−Ethenomorphinan−7−methanol,17−(cyclopropylmethyl)−α−(1,1−dimethylethyl)−4,5−epoxy−18,19−dihydro−3−hydroxy−6−methoxy−α−methyl−,−	9
Melting Point	~217 °C	12
pKa	8.5 and 10.0	12
ATC Codes	N02AE01, N07BC01, N07BC51	9
FDA UNII	40D3SCR4GZ	9

Pharmacology: Mechanism of Action and Pharmacodynamic Profile

Receptor Binding and Activity: A Multi-Receptor Interaction

The clinical effects of buprenorphine are dictated by its complex interactions with multiple subtypes of opioid receptors in the central nervous system and other tissues.

Partial Agonism at the Mu-Opioid (μ) Receptor

Buprenorphine is a partial agonist at the μ-opioid receptor.[4] This means that while it binds to and activates the receptor, it does so with a lower level of intrinsic activity compared to full agonists like morphine, heroin, or methadone.[4] This partial activation is sufficient to produce key therapeutic effects, including potent analgesia and the suppression of opioid withdrawal symptoms and cravings.[5] At the same time, it generates weaker euphoric effects and, most critically, less respiratory depression than full agonists, forming the basis of its improved safety profile.[4]

Antagonism at the Kappa-Opioid (κ) Receptor

In addition to its action at the μ-receptor, buprenorphine functions as an antagonist at the κ-opioid receptor.[14] Activation of the kappa system is associated with dysphoria, stress, and anhedonia, which are key drivers of relapse in substance use disorders. By blocking this receptor, buprenorphine may mitigate these negative affective states.[16] This kappa-antagonism is believed to contribute significantly to its favorable tolerability profile and is a primary mechanism underlying its emerging off-label use as a treatment for mood disorders, particularly treatment-resistant depression.[16] This suggests a dual mechanism in OUD treatment: the

μ-agonist activity addresses the negative reinforcement pathway (avoiding withdrawal), while the κ-antagonist activity may blunt the negative affective states that promote continued drug use.

Activity at Delta (δ) and ORL-1 Receptors

Buprenorphine also interacts with other opioid receptors, though the clinical significance is less well-defined. It is a weak antagonist at the delta (δ) opioid receptor and an agonist at the opioid receptor-like (ORL-1) receptor.[11] The lack of delta-agonist activity has been proposed to explain why tolerance to buprenorphine's effects may develop more slowly than with other opioids.[18] Meanwhile, its agonist activity at the ORL-1 receptor may contribute to its analgesic effects, produce less constipation than typical opioids, and potentially slow the development of analgesic tolerance.[11]

The "Ceiling Effect": Cornerstone of a Favorable Safety Profile

A defining pharmacodynamic feature of buprenorphine is its "ceiling effect," a direct result of its partial agonism at the μ-receptor.[2] As the dose of buprenorphine is increased, its opioid-mediated effects—particularly respiratory depression and euphoria—plateau and do not continue to increase linearly beyond a certain dosage level.[4] This ceiling is generally observed at therapeutic doses used for OUD, typically around 16-24 mg per day, with some studies noting the plateau at 32 mg.[14] This property substantially lowers the risk of fatal overdose in monotherapy when compared to full agonists like methadone, which exhibit a linear dose-response relationship for respiratory depression.[13]

It is imperative to recognize a critical caveat: this protective ceiling effect can be significantly attenuated or completely overcome when buprenorphine is co-administered with other central nervous system (CNS) depressants, most notably benzodiazepines and alcohol.[13] The additive depressant effects can lead to severe respiratory depression, coma, and death, a risk that is a major focus of clinical warnings.[22]

High Binding Affinity and Slow Dissociation: Implications for Efficacy and Risk

Buprenorphine's interaction with the μ-receptor is characterized by two additional properties that are central to its clinical use: extremely high binding affinity and very slow dissociation kinetics.

High Affinity

Buprenorphine binds to the μ-receptor with an affinity that is substantially higher than that of most other opioids, including morphine, methadone, and heroin.[24] This powerful attraction to the receptor has two profound and opposing clinical consequences.

1. Therapeutic Blockade: Once bound, buprenorphine is difficult to displace. This allows it to effectively occupy the receptors and block other opioids from binding. If a person on a stable maintenance dose of buprenorphine uses heroin, for example, the heroin will be unable to bind to the μ-receptors and produce its characteristic euphoric effect. This blockade diminishes the reinforcing properties of illicit opioid use and is a key therapeutic benefit.[2]
2. Precipitated Withdrawal: The same high affinity that provides a therapeutic blockade becomes a significant clinical risk during treatment initiation. If buprenorphine is administered to an individual who is physically dependent on a full opioid agonist (e.g., heroin, fentanyl) and still has that agonist in their system, buprenorphine will aggressively displace the full agonist from the μ-receptors.[4] Because buprenorphine has lower intrinsic activity, this displacement results in a rapid and substantial net decrease in receptor stimulation, precipitating an acute and often severe withdrawal syndrome.[4] This phenomenon is not merely an adverse effect but the direct, predictable consequence of its high-affinity binding. To avoid this, clinical protocols mandate that buprenorphine induction must be delayed until the patient is in a state of mild to moderate withdrawal, ensuring that a sufficient number of receptors are unoccupied.[2]

Slow Dissociation

Complementing its high affinity, buprenorphine dissociates from the μ-receptor very slowly.[13] This "tight binding" is a primary contributor to its long duration of action, which can extend from 24 to 72 hours depending on the dose.[11] This pharmacokinetic advantage allows for convenient daily or even alternate-day dosing schedules, which can improve patient adherence and quality of life compared to shorter-acting medications.[4]

In synthesis, buprenorphine's pharmacology creates a unique therapeutic niche. Full agonists like methadone control withdrawal but carry a high overdose risk. Full antagonists like naltrexone block opioid effects but offer no withdrawal relief, often leading to poor adherence. Buprenorphine combines the most desirable attributes of both classes: its partial agonism is sufficient to suppress withdrawal, its high affinity provides a blockade effect, its ceiling effect offers a margin of safety, and its slow dissociation permits less frequent dosing. It is the synergy of these four interconnected properties that establishes buprenorphine as a uniquely suitable agent for office-based OUD treatment.

Pharmacokinetics: Absorption, Distribution, Metabolism, and Excretion (ADME)

Absorption and Bioavailability

The route of administration is the primary determinant of buprenorphine's absorption and bioavailability. When administered orally, buprenorphine undergoes extensive first-pass metabolism in the gut wall and liver, resulting in very poor bioavailability and a lack of clinical effect.[1] To overcome this, formulations are designed for transmucosal (sublingual or buccal) or parenteral administration.

Sublingual (SL) and buccal (inside the cheek) routes allow the drug to be absorbed directly into the systemic circulation, bypassing the gastrointestinal tract and liver, thus achieving therapeutic plasma concentrations.[13] The absolute bioavailability of sublingual buprenorphine is subject to high inter-individual variability but is generally estimated to be in the range of 30% to 50%.[28] Newer formulations, such as the Zubsolv sublingual tablet, have been developed to offer improved bioavailability compared to older tablet formulations.[15] The time to reach peak plasma concentration (

Tmax​) after sublingual administration is also variable, typically ranging from 40 minutes to 4 hours.[1] Parenteral routes, including intravenous (IV), intramuscular (IM), and subcutaneous (SC), provide high, predictable bioavailability.[25]

Distribution, Lipophilicity, and Protein Binding

Buprenorphine is a highly lipophilic (fat-soluble) molecule.[7] This property facilitates its rapid distribution throughout the body, including efficient penetration of the blood-brain barrier to exert its effects on the central nervous system.[11] It has a large apparent volume of distribution, estimated at 188 to 335 L following IV administration, indicating extensive tissue uptake.[7] In the bloodstream, buprenorphine is highly bound to plasma proteins (approximately 96%), primarily alpha- and beta-globulins.[1]

Metabolism: The Central Role of Cytochrome P450 3A4

Buprenorphine is extensively metabolized in the liver, with the cytochrome P450 3A4 (CYP3A4) isoenzyme playing the principal role.[1] The primary metabolic pathway is N-dealkylation, which converts buprenorphine into its major active metabolite,

norbuprenorphine.[1] Although norbuprenorphine is itself a potent full

μ-opioid agonist, it penetrates the blood-brain barrier poorly and therefore is not thought to contribute significantly to the central clinical effects of the parent drug.[6] Both buprenorphine and norbuprenorphine subsequently undergo conjugation with glucuronic acid (glucuronidation) to form inactive metabolites that are then prepared for elimination.[15] The critical role of CYP3A4 in buprenorphine's clearance is the basis for the majority of its clinically significant pharmacokinetic drug-drug interactions.[13]

Elimination and Half-Life

The terminal elimination half-life (t1/2​) of buprenorphine is notably long and variable, with mean values reported across a wide range of 3 to 44 hours.[1] Following sublingual administration, the average half-life is typically cited as being between 24 and 42 hours, with some estimates extending up to 70 hours.[6] This prolonged half-life is a function of both its slow dissociation from opioid receptors and its sequestration in lipophilic tissues, from which it is slowly released back into circulation.[11]

Elimination of buprenorphine and its metabolites occurs predominantly via the feces through biliary excretion, with only a smaller fraction (approximately 10-30%) being excreted in the urine.[1] Very little of the drug is excreted unchanged.[9] This long and variable half-life presents a dual-edged clinical reality. It is advantageous for maintenance therapy, allowing for stable plasma levels with daily dosing. However, it complicates overdose management, as the drug's effects are prolonged, and it necessitates a very gradual tapering schedule when discontinuing therapy to avoid a protracted withdrawal syndrome.[21]

Pharmacokinetics in Special Populations

• Hepatic Impairment: Because the liver is the primary site of metabolism, patients with moderate to severe hepatic impairment exhibit reduced clearance and elevated plasma concentrations of buprenorphine. Dose adjustments are often necessary, and some buprenorphine products are not recommended for use in patients with severe hepatic disease.[27]
• Renal Impairment: Buprenorphine pharmacokinetics are not significantly altered by renal impairment. Therefore, dose adjustments are generally not required for patients with kidney disease.[1]
• Pregnancy: Pharmacokinetic changes during pregnancy can alter buprenorphine disposition, with evidence suggesting that higher doses may be required to maintain therapeutic plasma concentrations and prevent withdrawal. This remains an active area of clinical investigation.[34]

The high inter-individual variability observed in the bioavailability of transmucosal buprenorphine is a significant clinical challenge.[28] It means that a standard dose can produce vastly different plasma levels and clinical responses in different patients, complicating titration and potentially leading to either undertreatment or excessive side effects. This pharmacokinetic unpredictability has been a primary driver for the development of alternative delivery systems. Long-acting injectable (LAI) and implantable formulations bypass the variable transmucosal absorption step entirely, delivering the drug directly into the body to achieve more consistent and predictable plasma concentrations over extended periods.[36] This represents a direct pharmaceutical solution to a fundamental pharmacokinetic limitation of the original formulations.

Table 2: Comparative Pharmacokinetic Parameters of Buprenorphine Formulations

Parameter	Intravenous (IV)	Sublingual (SL)	Buccal	Transdermal
Bioavailability	100% (by definition)	~30-50% (highly variable)	~28% (highly variable)	Low, sustained delivery
Tmax​ (Time to Peak)	~10 minutes	1-4 hours	~2.5-3 hours	>17 hours to detect
Mean Cmax​ (Peak Conc.)	High, dose-dependent	Lower than IV	Lower than IV/SL	Low, steady-state
Elimination Half-Life (t1/2​)	~2-7 hours	~24-42 hours	~24-42 hours	~30 hours
Primary Use Case	Acute pain (hospital)	OUD, Pain	Pain, OUD	Chronic Pain

The combination products containing naloxone (e.g., Suboxone) are a prime example of formulation design leveraging pharmacokinetic principles. The abuse-deterrent mechanism relies on a "pharmacokinetic firewall." When taken sublingually as directed, buprenorphine is absorbed with sufficient bioavailability to be effective, while naloxone, which has extremely poor sublingual bioavailability and is subject to extensive first-pass metabolism, remains clinically inert.[13] However, if the product is crushed and injected, both drugs bypass this firewall and become highly bioavailable. The antagonist effects of naloxone then predominate, precipitating withdrawal and deterring this route of misuse.[23]

Clinical Applications and Therapeutic Efficacy

Treatment of Opioid Use Disorder (OUD)

Buprenorphine is an FDA-approved, first-line medication for the treatment of OUD.[5] It functions as an agonist substitution therapy, providing a medically supervised, safer, and longer-acting opioid to replace the use of illicit, short-acting opioids like heroin or fentanyl.[7] Its efficacy is well-established and stems from its ability to suppress withdrawal symptoms, reduce cravings, and block the euphoric effects of other opioids, all while having a lower potential for misuse and a superior safety profile compared to full agonists.[5] Buprenorphine-based MOUD is associated with significant public health benefits, including reductions in illicit opioid use, overdose mortality, criminal activity, and the transmission of infectious diseases such as HIV and hepatitis C.[6] For optimal outcomes, it should be integrated into a comprehensive treatment plan that includes counseling and psychosocial support.[5]

The clinical management of buprenorphine for OUD typically involves three phases:

• Induction: The initial phase involves carefully transitioning the patient from their opioid of abuse onto buprenorphine. This process must be timed precisely to avoid precipitated withdrawal. The patient must exhibit objective signs of mild-to-moderate withdrawal before the first dose is administered.[2] The required abstinence period varies depending on the opioid used: approximately 12 hours for short-acting opioids like heroin and 48-72 hours or more for long-acting opioids like methadone.[14] To mitigate the discomfort and risk of traditional induction, particularly with high-potency fentanyl, newer protocols such as "microdosing" or "low-dose induction" are being actively investigated. These methods involve starting with very small doses of buprenorphine while the patient continues to use their primary opioid, gradually increasing the buprenorphine dose over several days to achieve a therapeutic level without causing withdrawal.[20]
• Stabilization: In this phase, the buprenorphine dose is titrated to an effective level that eliminates cravings and withdrawal symptoms with minimal side effects. Due to the drug's long half-life, once a patient is stable on a daily dose, alternate-day dosing may be considered.[4]
• Maintenance: The patient continues on a steady, effective dose for an extended period. The duration of maintenance therapy is individualized and can be indefinite, as OUD is increasingly recognized as a chronic medical condition.[4]

Management of Acute and Chronic Pain

Buprenorphine is also an effective analgesic, approved by the FDA for the management of acute pain severe enough to require an opioid and for moderate-to-severe chronic pain that has not responded to other treatments.[2] Its potency is estimated to be 25 to 50 times that of morphine.[11] Despite being a partial

μ-agonist, it demonstrates full analgesic efficacy at therapeutic doses, and its pain-relieving effects are not limited by a ceiling in the same way its respiratory depressant effects are.[11]

The therapeutic goals for pain management differ significantly from those for OUD, and this is reflected in the formulations and dosing strategies employed. For pain, the objective is to provide consistent analgesia using the lowest effective dose. This has led to the development of specific formulations for pain management, which are distinct from the high-dose products used for OUD. These include:

• Buprenex: An injectable formulation for acute pain, typically used in a hospital setting.[3]
• Butrans: A transdermal patch that delivers a low, continuous dose of buprenorphine over seven days for the management of chronic pain.[3]
• Belbuca: A buccal film that adheres to the inside of the cheek, providing sustained release for chronic pain.[3]

It is a critical safety issue that the high-dose sublingual formulations intended for OUD are not appropriate for treating pain in opioid-naïve individuals, as this carries a significant risk of overdose.[27]

Emerging and Off-Label Uses: Treatment-Resistant Depression and Anxiety

A growing body of evidence supports the off-label use of buprenorphine for psychiatric conditions, particularly treatment-resistant depression (TRD).[17] Clinical observations of mood improvement in patients with OUD receiving buprenorphine prompted further investigation. This research has identified its antagonist activity at the

κ-opioid receptor as the likely mechanism for its antidepressant effects.[17] Studies have reported rapid and significant improvements in depressive symptoms, including depressed mood, anhedonia, and fatigue, as well as marked reductions in suicidal ideation, even in patients without a substance use disorder.[17]

Similarly, buprenorphine has been observed to have anxiolytic (anti-anxiety) properties, particularly in patients with co-occurring OUD and anxiety disorders.[45] The mechanism may involve modulation of various neurotransmitter systems involved in emotional regulation.[45] This area represents a compelling example of "reverse translation," where clinical observations have driven basic science inquiry into novel therapeutic applications for an existing drug.

Summary of Key Clinical Trial Findings

The clinical development of buprenorphine is ongoing. Current Phase 2 and 3 clinical trials are focused on several key areas: identifying optimal dosing strategies for OUD in the context of the fentanyl crisis, evaluating relapse prevention strategies that combine buprenorphine with the antagonist naltrexone, and refining novel induction methods like microdosing for use in emergency department settings.[40] Furthermore, completed trials have demonstrated the feasibility and effectiveness of using telemedicine to deliver buprenorphine-based MOUD, often integrating it with other essential health services like pre-exposure prophylaxis (PrEP) for HIV and treatment for hepatitis C.[47] This reflects a significant paradigm shift toward integrated, accessible, and remote management of OUD, treating it like other chronic medical conditions.

Buprenorphine Formulations: A Comparative Analysis

The therapeutic applications of buprenorphine are supported by a diverse array of pharmaceutical formulations, each designed with specific clinical goals, delivery mechanisms, and risk-mitigation features. These can be broadly categorized into monotherapy products (containing only buprenorphine) and combination products (containing buprenorphine and the opioid antagonist naloxone). The evolution from daily-dosed oral products to long-acting parenteral formulations reflects a broader trend in chronic disease management, aiming to improve adherence, reduce treatment burden, and enhance patient outcomes by transforming OUD care from a daily responsibility to a background, medically managed state.

Monotherapy Products (Buprenorphine Only)

• Sublingual Tablets (e.g., Subutex, generics): Historically, buprenorphine-only sublingual tablets were the standard for inducing patients onto MOUD.[29] They are still sometimes preferred for use during pregnancy to avoid fetal exposure to naloxone, although naloxone is now considered safe in pregnancy by most experts.[29] The brand name Subutex has been discontinued in the U.S., but generic versions remain available.[42] These mono-products carry a higher risk of being diverted for injection misuse compared to combination formulations.[49]
• Injectable Formulations:
• Buprenex (IV/IM): A low-dose, short-acting injectable solution approved for the management of acute pain, typically in a supervised medical setting.[3]
• Sublocade (SC Extended-Release): A monthly subcutaneous injection for OUD maintenance. The liquid formulation forms a solid depot under the skin, from which buprenorphine is slowly released over the course of a month. It is indicated for patients who are already stable on a transmucosal buprenorphine product. Its primary advantages are the elimination of daily dosing, which improves adherence, and the prevention of diversion of take-home medication.[36]
• Brixadi (SC Extended-Release): Another subcutaneous injectable for OUD, available in both weekly and monthly dosing options, providing flexibility in treatment.[39]
• Transdermal Patch (e.g., Butrans): A patch applied to the skin and worn for seven days. It delivers a continuous, low dose of buprenorphine and is approved for the management of chronic pain.[3]
• Buccal Film (e.g., Belbuca): A film that adheres to the mucosal lining of the cheek, providing sustained drug delivery for chronic pain management.[3]
• Implant (e.g., Probuphine): Consists of four small rods surgically implanted under the skin of the upper arm, releasing a low, steady dose of buprenorphine for six months. It is approved for OUD maintenance, but its use has largely been superseded by the less invasive long-acting injectables.[25]

Combination Products (Buprenorphine/Naloxone)

The majority of transmucosal products for OUD are combination formulations containing both buprenorphine and naloxone. The inclusion of naloxone is a deliberate public health strategy to deter misuse.

• Rationale for Combination: The opioid antagonist naloxone is added specifically to discourage parenteral (injection) or intranasal (snorting) abuse of the medication.[5]
• Mechanism of Deterrence: As described by its "pharmacokinetic firewall," when the product is used as directed (dissolved under the tongue or in the cheek), the buprenorphine is absorbed effectively, but the naloxone has negligible bioavailability and thus no clinical effect.[13] However, if the product is crushed and injected or snorted, the naloxone becomes highly bioavailable. In an individual with opioid dependence, this will block the euphoric effects of buprenorphine and can precipitate an immediate and unpleasant withdrawal syndrome, making these routes of misuse aversive.[4]
• Available Formulations:
• Sublingual Film (e.g., Suboxone): The most widely prescribed formulation for OUD maintenance. It is a thin film that dissolves under the tongue.[29]
• Sublingual Tablet (e.g., Zubsolv, generics): Tablets that dissolve under the tongue. Some newer branded tablets like Zubsolv were designed to offer higher bioavailability than the original Suboxone tablets.[15]
• Buccal Film (e.g., Bunavail): A film designed to adhere to the inside of the cheek.[15]

The market dominance of these combination products for OUD reflects a risk-benefit calculation by regulators and clinicians. It prioritizes the societal benefit of reducing the potential for medication diversion and misuse over the slightly simpler formulation of the mono-product, establishing the buprenorphine/naloxone combination as the standard of care for the vast majority of patients.[37]

Table 3: Buprenorphine Formulations and Brand Names in the U.S.

Indication	Active Ingredient(s)	Formulation	Brand Name(s)	Administration
Opioid Use Disorder	Buprenorphine/Naloxone	Sublingual Film	Suboxone, Cassipa (discont.)	Daily, Sublingual
	Buprenorphine/Naloxone	Sublingual Tablet	Zubsolv, Generics	Daily, Sublingual
	Buprenorphine/Naloxone	Buccal Film	Bunavail (discont.)	Daily, Buccal
	Buprenorphine	Sublingual Tablet	Subutex (discont.), Generics	Daily, Sublingual (Induction/Pregnancy)
	Buprenorphine	SC Extended-Release Inj.	Sublocade	Monthly, Subcutaneous
	Buprenorphine	SC Extended-Release Inj.	Brixadi	Weekly or Monthly, Subcutaneous
	Buprenorphine	Subdermal Implant	Probuphine (discont.)	Every 6 months, Subdermal
Chronic Pain	Buprenorphine	Transdermal Patch	Butrans	Every 7 days, Transdermal
	Buprenorphine	Buccal Film	Belbuca	Every 12 hours, Buccal
Acute Pain	Buprenorphine	Injectable Solution	Buprenex	Every ~6 hours, IV/IM

Safety Profile and Adverse Drug Events

Common and Serious Adverse Reactions

The adverse effect profile of buprenorphine shares many characteristics with other opioids.

• Common Side Effects: Frequently reported adverse reactions include constipation, nausea, vomiting, headache, dizziness, drowsiness, fatigue, sweating, and dry mouth.[5]
• Serious Side Effects: More severe risks include life-threatening respiratory depression, overdose (particularly with concomitant CNS depressant use), adrenal insufficiency, physical and psychological dependence, and withdrawal syndromes upon discontinuation.[2] Prolonged use during pregnancy can lead to neonatal opioid withdrawal syndrome (NOWS) in the newborn.[5] Formulation-specific serious effects include pain, itching, and potential nerve damage at implant or injection sites.[5]

Key Warnings and Precautions (Black Box Warnings)

The FDA has mandated several black box warnings for buprenorphine products to highlight the most critical risks associated with their use.

• Addiction, Abuse, and Misuse: As a Schedule III opioid, buprenorphine exposes users to the risks of addiction, abuse, and misuse, which can result in overdose and death. This risk is present even when the medication is prescribed appropriately, and all patients should be monitored for the development of these behaviors.[3]
• Life-Threatening Respiratory Depression: This is the most serious acute risk associated with buprenorphine. While the ceiling effect on respiratory depression provides a margin of safety in monotherapy, this protection is lost when buprenorphine is combined with other CNS depressants like benzodiazepines or alcohol. This combination can lead to profound, life-threatening respiratory depression.[13] The risk is also elevated in opioid-naïve individuals and in cases of accidental pediatric exposure.[27]
• Neonatal Opioid Withdrawal Syndrome (NOWS): Prolonged maternal use of buprenorphine during pregnancy will lead to physical dependence in the fetus. After birth, the infant is at risk for NOWS, a potentially life-threatening condition characterized by irritability, poor feeding, and seizures. It is an expected and treatable outcome that requires management by neonatal experts.[3]
• Hepatotoxicity: Cases of cytolytic hepatitis and hepatitis with jaundice have been reported. Liver function tests should be performed prior to initiating therapy and monitored periodically during treatment, especially in patients with pre-existing liver conditions like hepatitis B or C, or those using other potentially hepatotoxic substances.[5]
• Dental Health Complications: The FDA has issued a specific warning regarding a risk of serious dental problems, including tooth decay, cavities, oral infections, and tooth loss, associated with transmucosal buprenorphine formulations.[5] This is thought to be due to the acidic nature of the medication and its prolonged contact time with teeth and oral mucosa. Patients should be counseled on proper oral hygiene, which includes gently rinsing the mouth with water after the medication has fully dissolved and waiting at least one hour before brushing their teeth.[51] This adverse effect is a clear example of a long-term, formulation-specific risk identified through post-marketing surveillance, highlighting that the understanding of a drug's safety profile evolves over its lifecycle. It also underscores a key safety difference between transmucosal and parenteral formulations.
• Unintentional Pediatric Exposure: Due to the high potency of buprenorphine, accidental ingestion by a child can cause severe and potentially fatal respiratory depression. Strict adherence to safe storage practices is essential.[5]

Overdose Management and the Role of Naloxone

An overdose of buprenorphine typically presents with the classic opioid triad of miosis (pinpoint pupils), depressed level of consciousness, and respiratory depression.[21] The standard of care for management is immediate respiratory support and the administration of the opioid antagonist naloxone.[21] However, due to buprenorphine's very high affinity for and slow dissociation from the

μ-receptor, reversing its effects can be more challenging than reversing a full agonist overdose. Consequently, higher and/or repeated doses of naloxone, or even a continuous naloxone infusion, may be required to maintain adequate ventilation until the buprenorphine is cleared.[7] To mitigate overdose risk, patients receiving buprenorphine and their caregivers should be educated on recognizing the signs of an overdose and should be co-prescribed naloxone for emergency use.[3]

The safety profile of buprenorphine is thus paradoxical. It is inherently safer than full agonists in a monotherapy context due to its ceiling effect, yet this safety margin is largely erased by concomitant use of CNS depressants. This context-dependent safety profile demands a nuanced clinical understanding that avoids oversimplification.

Clinically Significant Drug Interactions

Buprenorphine is subject to numerous drug interactions, with over 700 potential interactions identified.[52] These can be categorized by their underlying mechanism to facilitate clinical risk management. The clinical approach to these interactions has evolved from one of simple avoidance to a more sophisticated, mechanism-based risk assessment, which allows for safer co-prescription when clinically necessary.

Pharmacodynamic Interactions: Additive CNS Depression

These interactions occur when two drugs with similar physiological effects are taken together, leading to an amplified or additive effect.

• Benzodiazepines: This is the most clinically significant and dangerous interaction. The co-administration of buprenorphine with benzodiazepines (e.g., alprazolam, diazepam, lorazepam) dramatically increases the risk of severe sedation, life-threatening respiratory depression, coma, and death.[13] The mechanism is a purely additive pharmacodynamic depression of the central nervous system.[1] While this combination was once considered an absolute contraindication, current guidance recognizes that withholding buprenorphine from a patient with OUD or withholding a benzodiazepine from a patient with a severe anxiety disorder can also cause significant harm. Therefore, co-prescription may be undertaken with extreme caution, using the lowest possible doses of both agents and with rigorous patient monitoring for sedation.[13]
• Alcohol: Alcohol is a potent CNS depressant that synergistically increases the sedative and respiratory depressant effects of buprenorphine, elevating the risk of overdose.[5]
• Other CNS Depressants: This category includes other opioids, sedative-hypnotics, antipsychotics, certain antidepressants, muscle relaxants, and sedating antihistamines. All can contribute to additive CNS depression and should be used with caution in patients taking buprenorphine.[31]

Pharmacokinetic Interactions: CYP3A4 Metabolism

These interactions occur when one drug alters the metabolism, and therefore the plasma concentration, of another. As buprenorphine is primarily metabolized by CYP3A4, drugs that affect this enzyme are of primary concern.

• CYP3A4 Inhibitors: Drugs that inhibit CYP3A4 will slow the metabolism of buprenorphine, causing its plasma levels to rise. This can lead to increased effects, toxicity, and a higher risk of overdose.[13] Clinically important inhibitors include azole antifungals (e.g., ketoconazole, fluconazole), macrolide antibiotics (e.g., erythromycin, clarithromycin), and certain antiretroviral protease inhibitors.[31] Grapefruit juice is also a potent inhibitor.[31] When co-prescribing with a strong inhibitor, monitoring and potential reduction of the buprenorphine dose may be necessary.
• CYP3A4 Inducers: Drugs that induce or increase the activity of CYP3A4 will accelerate the metabolism of buprenorphine, causing its plasma levels to fall. This can lead to a loss of therapeutic effect and may precipitate opioid withdrawal symptoms.[13] Clinically important inducers include certain anticonvulsants (e.g., carbamazepine, phenytoin, phenobarbital), the antibiotic rifampin, and the herbal supplement St. John's Wort.[31] When co-prescribing with a strong inducer, an increased dose of buprenorphine may be required to maintain efficacy.

Notably, the risk of these pharmacokinetic interactions is formulation-dependent. Sublingual buprenorphine is subject to first-pass metabolism, making it more vulnerable to CYP3A4 interactions in the gut and liver.[59] In contrast, subcutaneous extended-release formulations like Sublocade bypass first-pass metabolism. Pharmacokinetic modeling predicts that the impact of CYP3A4 inhibitors or inducers on these formulations is significantly less pronounced and may not be clinically meaningful, making them a potentially more stable option for patients on complex medication regimens.[59]

Risk of Serotonin Syndrome with Serotonergic Agents

Buprenorphine has serotonergic activity and, when combined with other serotonergic medications, can increase the risk of serotonin syndrome, a rare but potentially life-threatening condition.[61] This risk exists with antidepressants such as SSRIs (e.g., sertraline, escitalopram), SNRIs (e.g., duloxetine), tricyclic antidepressants, and especially MAOIs.[56] Patients should be monitored for symptoms such as mental status changes (confusion, agitation), autonomic hyperactivity (fever, sweating, tachycardia), and neuromuscular abnormalities (tremor, rigidity).[62]

Interactions with Opioid Antagonists

Full opioid antagonists, such as naltrexone, will block the effects of buprenorphine and will precipitate withdrawal in a patient maintained on buprenorphine therapy.[13]

Regulatory Status and Historical Perspective

Development History and Key Approval Milestones

Buprenorphine was first synthesized in the United Kingdom in the 1970s as a novel analgesic with high potency and a unique receptor profile.[6] After its patenting in 1965, its potential for treating opioid dependence was recognized in a landmark 1978 paper.[2] Its regulatory journey in the United States began with its approval in 1985 as Buprenex, an injectable analgesic initially classified as a Schedule V narcotic.[48]

A pivotal moment occurred in October 2002, when the U.S. Food and Drug Administration (FDA) approved the first high-dose sublingual tablet formulations specifically for the treatment of OUD: Subutex (buprenorphine monotherapy) and Suboxone (buprenorphine/naloxone combination).[48] This approval, coupled with new legislation, fundamentally changed the landscape of addiction treatment. The following two decades saw a wave of innovation and approvals for new formulations designed to improve adherence, reduce diversion risk, and expand clinical applications, including the Butrans transdermal patch for pain (2010), the Probuphine subdermal implant (2016), and the long-acting subcutaneous injections Sublocade (2017) and Brixadi (2023).[36]

Controlled Substance Scheduling and Rationale

In the United States, buprenorphine is classified as a Schedule III controlled substance under the Controlled Substances Act.[2] This scheduling reflects the determination that it has a currently accepted medical use, a lower potential for abuse compared to drugs in Schedules I and II (such as heroin and fentanyl), and that its abuse may lead to moderate or low physical dependence or high psychological dependence.[3] This classification distinguishes it from methadone, another key medication for OUD, which is in the more restrictive Schedule II category.[67]

The Evolution of U.S. Prescribing Legislation: From DATA 2000 to the MAT Act

The regulatory history of buprenorphine for OUD in the U.S. mirrors a profound, multi-decade policy shift from viewing addiction as a moral or criminal failing to treating it as a chronic medical disease.

• Pre-2000: Federal law restricted the use of opioids for treating opioid addiction to highly regulated and often stigmatized Opioid Treatment Programs (OTPs), commonly known as methadone clinics.[69]
• The Drug Addiction Treatment Act of 2000 (DATA 2000): This was a landmark piece of legislation that created a new paradigm for addiction care. DATA 2000 allowed qualified physicians to obtain a special waiver from the Drug Enforcement Administration (DEA), known as the "X-waiver," to prescribe Schedule III-V opioids (effectively, buprenorphine) for OUD from their own offices.[69] This moved addiction treatment into mainstream medical settings. However, the requirements for obtaining the waiver, including an 8-hour training course and strict patient limits, were later recognized as significant barriers that limited the number of prescribers and perpetuated stigma.[67]
• The Mainstreaming Addiction Treatment (MAT) Act: In a monumental step to further integrate addiction care into mainstream medicine, the MAT Act was signed into law as part of the Consolidated Appropriations Act of 2023. Effective December 29, 2022, this legislation eliminated the federal X-waiver requirement.[71] Now, any prescriber with a standard DEA registration is authorized to prescribe buprenorphine for OUD, subject only to state law. This change dramatically expanded the potential pool of providers and aimed to normalize the treatment of OUD as a standard component of medical practice.[73]

Recent FDA Labeling Modifications and Their Clinical Impact

The clinical and regulatory landscape for buprenorphine continues to evolve in response to the ongoing opioid crisis, which is now dominated by high-potency synthetic opioids like fentanyl. In late 2023, recognizing that the old standard doses of buprenorphine were often insufficient to treat individuals using fentanyl, the FDA issued new recommendations for the labeling of transmucosal buprenorphine products.[35]

The agency noted that previous labeling language, which stated that doses higher than 24 mg daily had not been shown to provide a clinical advantage, was being misinterpreted by clinicians and payers as an absolute maximum dose.[35] This was creating a barrier to effective treatment. Supported by new evidence demonstrating better outcomes with higher doses in the fentanyl era, the FDA clarified that there is no mandated maximum dosage.[35] The new recommended labeling states that doses should be individualized based on clinical response and that daily doses higher than 24 mg "may be appropriate for some patients".[35] This action represents a critical, evidence-based regulatory response to the changing realities of the illicit drug supply, ensuring that clinical practice can adapt to meet patients' needs.

Conclusion and Future Directions

Buprenorphine is a pharmacologically unique and clinically indispensable medication. Its identity as a high-affinity, slow-dissociating partial μ-opioid agonist and κ-opioid antagonist provides a unifying explanation for its dual efficacy in pain management and Opioid Use Disorder, its advantageous safety profile relative to full agonists, and its distinct clinical challenges, such as the risk of precipitated withdrawal. Over the past several decades, it has become a life-saving tool that has been central to a public health revolution, moving the treatment of OUD from segregated clinics into the mainstream of medical practice.

Despite its established role, research and development continue to refine its use and explore its full therapeutic potential. Future directions in the field are focused on several key areas:

• Formulation Innovation: The development of long-acting injectable and implantable formulations has already transformed treatment by improving adherence and eliminating diversion risk. Ongoing research aims to optimize these technologies, potentially by extending the dosing interval of LAIs, which could further reduce the treatment burden for patients.[6]
• Optimizing Treatment for Fentanyl Use: The dominance of illicitly manufactured fentanyl requires a re-evaluation of traditional buprenorphine protocols. Active research is focused on establishing optimal dosing strategies and validating novel induction methods, such as microdosing, to safely and effectively transition patients from high-potency synthetic opioids onto buprenorphine.[20]
• Addressing Needs in Special Populations: More robust pharmacokinetic and safety data are needed for pregnant patients to better guide dosing, maintain maternal stability, and minimize the incidence and severity of Neonatal Opioid Withdrawal Syndrome.[34]
• Exploration of Psychiatric Applications: The promising preliminary evidence for buprenorphine's efficacy in treatment-resistant depression and anxiety, likely mediated by its kappa-antagonism, warrants large-scale, rigorous randomized controlled trials. Success in this area could establish a new therapeutic class for mood disorders and provide a new option for patients with co-occurring OUD and psychiatric conditions.[17]
• Overcoming Implementation Barriers: While the elimination of the federal X-waiver was a landmark achievement, significant barriers to access remain. Future efforts must focus on educating and supporting the newly expanded pool of potential prescribers, combating the persistent stigma surrounding OUD and its treatment, and ensuring equitable access to this life-saving medication for all populations.

In conclusion, buprenorphine stands as a testament to the power of pharmacological innovation to address pressing public health crises. Its continued study and thoughtful clinical application will remain essential to mitigating the harms of the opioid crisis and improving the lives of individuals with pain and addiction.

Works cited

1. Buprenorphine: clinical pharmacokinetics in the treatment of opioid dependence - PubMed, accessed July 15, 2025, https://pubmed.ncbi.nlm.nih.gov/15966752/
2. Buprenorphine - Wikipedia, accessed July 15, 2025, https://en.wikipedia.org/wiki/Buprenorphine
3. Buprenorphine: Uses, Dosage, Side Effects - Drugs.com, accessed July 15, 2025, https://www.drugs.com/buprenorphine.html
4. What is Buprenorphine? - UAMS Psychiatric Research Institute, accessed July 15, 2025, https://psychiatry.uams.edu/clinical-care/outpatient-care/cast/buprenorphine/
5. What is Buprenorphine? Side Effects, Treatment & Use - SAMHSA, accessed July 15, 2025, https://www.samhsa.gov/substance-use/treatment/options/buprenorphine
6. Buprenorphine Pharmacology Review: Update on Transmucosal and Long-Acting Formulations - PMC, accessed July 15, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC7442141/
7. Buprenorphine - StatPearls - NCBI Bookshelf, accessed July 15, 2025, https://www.ncbi.nlm.nih.gov/books/NBK459126/
8. www.ncbi.nlm.nih.gov, accessed July 15, 2025, https://www.ncbi.nlm.nih.gov/books/NBK459126/#:~:text=FDA%2DApproved%20Indications,-Buprenorphine%20is%20approved&text=and%20opioid%20dependence.-,This%20drug%20is%20used%20in%20agonist%20substitution%20treatment%E2%80%94a%20method,such%20as%20buprenorphine%20or%20methadone.
9. BUPRENORPHINE | 52485-79-7 - ChemicalBook, accessed July 15, 2025, https://www.chemicalbook.com/ChemicalProductProperty_EN_CB0279103.htm
10. CHEBI:3216 - buprenorphine - EMBL-EBI, accessed July 15, 2025, https://www.ebi.ac.uk/chebi/searchId.do?chebiId=CHEBI:3216
11. Pharmacokinetics and Local Tolerability of a Novel Sublingual ..., accessed July 15, 2025, https://academic.oup.com/painmedicine/article/20/1/143/4788299
12. CENTER FOR DRUG EVALUATION AND RESEARCH APPLICATION NUMBER: 21-306 CHEMISTRY REVIEW(S) - accessdata.fda.gov, accessed July 15, 2025, https://www.accessdata.fda.gov/drugsatfda_docs/nda/2010/021306Orig1s000ChemR.pdf
13. Buprenorphine for Opioid Use Disorder, accessed July 15, 2025, https://www.health.ny.gov/publications/0111.pdf
14. Buprenorphine Quick Start Guide - SAMHSA, accessed July 15, 2025, https://www.samhsa.gov/sites/default/files/quick-start-guide.pdf
15. Buprenorphine Formulations - :::::Pain Physician:::::, accessed July 15, 2025, https://www.painphysicianjournal.com/current/pdf?article=NTAwMQ%3D%3D&journal=109
16. Safety And Efficacy Of The Unique Opioid Buprenorphine For The Treatment Of Chronic Pain - PMC, accessed July 15, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC6917545/
17. Depression: What's Buprenorphine Got to Do With It? - Psychiatry Online, accessed July 15, 2025, https://psychiatryonline.org/doi/10.1176/appi.ajp-rj.2019.140202
18. Buprenorphine Hydrochloride | C29H42ClNO4 | CID 3033050 - PubChem, accessed July 15, 2025, https://pubchem.ncbi.nlm.nih.gov/compound/Subutex
19. Buprenorphine: Uses, Interactions, Mechanism of Action | DrugBank ..., accessed July 15, 2025, https://go.drugbank.com/drugs/DB00921
20. Buprenorphine/Naloxone (Suboxone®) Reference Guide for ED Providers - Meta:Phi, accessed July 15, 2025, https://www.metaphi.ca/wp-content/uploads/ED_OUD_ReferenceGuide.pdf
21. Buprenorphine; Naloxone | C48H62N2O8 | CID 11274356 - PubChem, accessed July 15, 2025, https://pubchem.ncbi.nlm.nih.gov/compound/Bunavail
22. Clinical Safety | BRIXADI® (buprenorphine) extended-release injection for subcutaneous use (CIII), accessed July 15, 2025, https://www.brixadihcp.com/safety/
23. Buprenorphine is a synthetic partial mu-receptor agonist. Examples of full opioid - BC Centre on Substance Use, accessed July 15, 2025, https://www.bccsu.ca/wp-content/uploads/2021/12/LOUDintheED-Pharmacology.pdf
24. www.ncbi.nlm.nih.gov, accessed July 15, 2025, https://www.ncbi.nlm.nih.gov/books/NBK459126/#:~:text=Mechanism%20of%20Action,-Buprenorphine%20is%20a&text=Buprenorphine%20exhibits%20high%2Daffinity%20binding,withdrawal%20symptoms%20for%20the%20patient.
25. Buprenorphine Pharmacology Review: Update on Transmucosal and Long-acting Formulations, accessed July 15, 2025, https://www.oregonpainguidance.org/wp-content/uploads/2018/02/JAM-Buprenorphine-Pharmacology-Review-Update-on-Transmucosal-and-Long-acting-Formulations.pdf
26. Pharmacology of Buprenorphine agonist antagonist explained and the cuase of withdrawal, accessed July 15, 2025, https://www.naabt.org/education/pharmacoloy_of_buprenorphine.cfm
27. HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use BUPRENORPHINE sublingua - Boehringer Ingelheim, accessed July 15, 2025, https://docs.boehringer-ingelheim.com/Prescribing%20Information/PIs/Roxane/Buprenorphine%20HCl%20Sublingual%20Tabs/10004964_01%20Buprenorphine%20HCl%20Sublingual%20Tabs.pdf
28. Human Pharmacokinetics of Intravenous, Sublingual, and Buccal Buprenorphine* | Journal of Analytical Toxicology | Oxford Academic, accessed July 15, 2025, https://academic.oup.com/jat/article/20/6/369/777488
29. Types of Buprenorphine Medications: Differences & How to Choose | Bicycle Health, accessed July 15, 2025, https://www.bicyclehealth.com/opioid-education/buprenorphine/medication-types
30. 022410Orig1s000 - accessdata.fda.gov, accessed July 15, 2025, https://www.accessdata.fda.gov/drugsatfda_docs/nda/2010/022410Orig1s000MedR.pdf
31. Drug interactions involving methadone and buprenorphine - Guidelines for the Psychosocially Assisted Pharmacological Treatment of Opioid Dependence - NCBI, accessed July 15, 2025, https://www.ncbi.nlm.nih.gov/books/NBK143177/
32. Common questions about buprenorphine - NHS, accessed July 15, 2025, https://www.nhs.uk/medicines/buprenorphine-for-pain/common-questions-about-buprenorphine/
33. This label may not be the latest approved by FDA. For current ..., accessed July 15, 2025, https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/022410s042lbl.pdf
34. Study Details | Impact of Pregnancy on Buprenorphine Pharmacokinetics and Pharmacodynamics | ClinicalTrials.gov, accessed July 15, 2025, https://clinicaltrials.gov/study/NCT02863601
35. FDA moves to change labeling on buprenorphine dosing - American Medical Association, accessed July 15, 2025, https://www.ama-assn.org/delivering-care/behavioral-health/fda-moves-change-labeling-buprenorphine-dosing
36. Buprenorphine and its formulations: a comprehensive review - PMC, accessed July 15, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC9392838/
37. Buprenorphine Formulations: A Practical Summary for Clinicians, accessed July 15, 2025, https://psychopharmacologyinstitute.com/section/buprenorphine-formulations-a-practical-summary-for-clinicians-2037-4003
38. Buprenorphine hydrochloride | DrugBank Online, accessed July 15, 2025, https://go.drugbank.com/salts/DBSALT000019
39. Buprenorphine - Alcohol and Drug Foundation, accessed July 15, 2025, https://adf.org.au/drug-facts/buprenorphine/
40. Opioid Use Disorders Recruiting Phase 2 / 3 Trials for Buprenorphine (DB00921), accessed July 15, 2025, https://go.drugbank.com/indications/DBCOND0069619/clinical_trials/DB00921?phase=2%2C3&status=recruiting
41. CIII NDC 12496-0757-5 BUPRENEX ... - accessdata.fda.gov, accessed July 15, 2025, https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/018401s027lbl.pdf
42. What are the different brands of buprenorphine? - Drugs.com, accessed July 15, 2025, https://www.drugs.com/medical-answers/different-brands-buprenorphine-3546572/
43. Can Suboxone Help With Major Depression? - National Addiction Specialists, accessed July 15, 2025, https://www.nationaladdictionspecialists.com/suboxone-for-major-depression/
44. Buprenorphine and Its Therapeutic Potential in Psychiatric Disorders, accessed July 15, 2025, https://www.psychiatrictimes.com/view/buprenorphine-and-its-therapeutic-potential-in-psychiatric-disorders
45. How Buprenorphine Effects Anxiety and Depression - Porch Light Health, accessed July 15, 2025, https://porchlighthealth.com/buprenorphine-anxiety-depression/
46. Anxiety Treatment of Opioid Dependent Patients with Buprenorphine: A Randomized, Double-blind, Clinical Trial - PMC, accessed July 15, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC5559992/
47. Opioids Use Completed Phase Trials for Buprenorphine (DB00921) | DrugBank Online, accessed July 15, 2025, https://go.drugbank.com/indications/DBCOND0046132/clinical_trials/DB00921?status=completed
48. BUPRENORPHINE (Trade Names: Buprenex®, Suboxone ..., accessed July 15, 2025, https://www.deadiversion.usdoj.gov/drug_chem_info/buprenorphine.pdf
49. Your Guide to the Buprenorphine Treatments Approved by the FDA, accessed July 15, 2025, https://joingroups.com/your-guide-to-the-buprenorphine-treatments-approved-by-the-fda/
50. en.wikipedia.org, accessed July 15, 2025, https://en.wikipedia.org/wiki/Buprenorphine#:~:text=Buprenorphine%20is%20available%20under%20the,treatment%20in%202018)%2C%20Sublocade%20(%252C%2520Sublocade%2520(&sa=D&source=editors&ust=1752567172051245&usg=AOvVaw1tYuU15_h0DFXEum9Jq2Sf)
51. FDA warns about dental problems with buprenorphine medicines dissolved in the mouth to treat opioid use disorder and pain, accessed July 15, 2025, https://www.fda.gov/drugs/drug-safety-and-availability/fda-warns-about-dental-problems-buprenorphine-medicines-dissolved-mouth-treat-opioid-use-disorder
52. Buprenorphine Interactions Checker - Drugs.com, accessed July 15, 2025, https://www.drugs.com/drug-interactions/buprenorphine.html
53. www.goodrx.com, accessed July 15, 2025, https://www.goodrx.com/buprenorphine/interactions#:~:text=Buprenorphine%20interactions%20can%20occur%20with%20several%20medications.,alprazolam%20(Xanax)%20and%20alcohol.
54. Is combining Buprenorphine and Benzodiazepines hazardous?, accessed July 15, 2025, https://cartyaddictioninternist.com/is-combining-buprenorphine-and-benzodiazepines-hazardous/
55. Medications to Avoid to Stop Suboxone Drug Interactions- HCRC - Health Care Resource Centers, accessed July 15, 2025, https://www.hcrcenters.com/blog/medications-you-cannot-take-with-buprenorphine-suboxone
56. Drug Interaction Report: buprenorphine, selegiline - Drugs.com, accessed July 15, 2025, https://www.drugs.com/interactions-check.php?drug_list=438-0,2051-0&professional=1
57. Alcohol, Benzodiazepines, and More: 9 Buprenorphine Interactions to Watch For - GoodRx, accessed July 15, 2025, https://www.goodrx.com/buprenorphine/interactions
58. Buprenorphine/naloxone Drug–Drug Interactions, accessed July 15, 2025, https://www.bccsu.ca/wp-content/uploads/2022/06/Buprenorphine-Naloxone-Drug-Drug-Interactions.pdf
59. Evaluation of Drug‐Drug Interaction Liability for Buprenorphine Extended‐Release Monthly Injection Administered by Subcutaneous Route, accessed July 15, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC8451859/
60. Evaluation of Drug-Drug Interaction Liability for Buprenorphine Extended-Release Monthly Injection Administered by Subcutaneous Route - PubMed, accessed July 15, 2025, https://pubmed.ncbi.nlm.nih.gov/33750027/
61. CONTRAINDICATIONS - accessdata.fda.gov, accessed July 15, 2025, https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/204442s002s004lbl.pdf
62. Buprenorphine and Zoloft Interactions - Drugs.com, accessed July 15, 2025, https://www.drugs.com/drug-interactions/buprenorphine-with-zoloft-438-0-2057-1348.html
63. Buprenorphine and escitalopram Interactions - Drugs.com, accessed July 15, 2025, https://www.drugs.com/drug-interactions/buprenorphine-with-escitalopram-438-0-1013-0.html
64. Timeline of Selected FDA Activities and Significant Events Addressing Substance Use and Overdose Prevention, accessed July 15, 2025, https://www.fda.gov/drugs/food-and-drug-administration-overdose-prevention-framework/timeline-selected-fda-activities-and-significant-events-addressing-substance-use-and-overdose
65. www.ncbi.nlm.nih.gov, accessed July 15, 2025, https://www.ncbi.nlm.nih.gov/books/NBK459126/#:~:text=Buprenorphine%20is%20categorized%20as%20a,chronic%20pain%20and%20opioid%20dependence.
66. Is buprenorphine an opiate / narcotic? - Drugs.com, accessed July 15, 2025, https://www.drugs.com/medical-answers/buprenorphine-opiate-narcotic-3543883/
67. Buprenorphine—A Primer for Prescribers and Pharmacists - CMS, accessed July 15, 2025, https://www.cms.gov/files/document/wbuprenorphinebooklet080814fpdf
68. What Schedule Drug Is Suboxone? - Bicycle Health, accessed July 15, 2025, https://www.bicyclehealth.com/suboxone-faq/what-schedule-drug-is-suboxone
69. Buprenorphine for office-based treatment of patients with opioid addiction - PubMed, accessed July 15, 2025, https://pubmed.ncbi.nlm.nih.gov/16118361/
70. Drug Addiction Treatment Act of 2000 | Technical Resources - aspr tracie, accessed July 15, 2025, https://asprtracie.hhs.gov/technical-resources/resource/6764/drug-addiction-treatment-act-of-2000-data-2000
71. Drug Addiction Treatment Act - Wikipedia, accessed July 15, 2025, https://en.wikipedia.org/wiki/Drug_Addiction_Treatment_Act
72. Improve Access to Care for Opioid Use Disorder: A Call to Eliminate the X-Waiver Requirement Now - PubMed Central, accessed July 15, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC8324519/
73. Mainstreaming Addiction Treatment (MAT) Act Signed into Law, accessed July 15, 2025, https://nhcenterforexcellence.org/resource/mainstreaming-addiction-treatment-mat-act-signed-into-law/
74. Mainstreaming Addiction Treatment Act and What it Means For Patients - ASHP, accessed July 15, 2025, https://www.ashp.org/Professional-Development/ASHP-Podcasts/Advocacy-Updates/Mainstreaming-Addiction-Treatment-Act-and-What-it-Means-For-Patients
75. FDA recommends changes to labeling for transmucosal buprenorphine products indicated to treat opioid use disorder, accessed July 15, 2025, https://www.fda.gov/drugs/drug-safety-and-availability/fda-recommends-changes-labeling-transmucosal-buprenorphine-products-indicated-treat-opioid-use
76. Buprenorphine - brand name list from Drugs.com, accessed July 15, 2025, https://www.drugs.com/ingredient/buprenorphine.html
77. Buprenorphine + naloxone | C29H41NO4 | CID 6321408 - PubChem, accessed July 15, 2025, https://pubchem.ncbi.nlm.nih.gov/compound/6321408
78. Buprenorphine [INN:BAN:JAN] - PubChem, accessed July 15, 2025, https://pubchem.ncbi.nlm.nih.gov/substance/135002732